The rationale and design of TransCon Growth Hormone for the treatment of growth hormone deficiency

Autor: Kennett Sprogøe, Eva Mortensen, David B Karpf, Jonathan A Leff

Publikováno v: Endocrine Connections, Vol 6, Iss 8, Pp 171-181 (2017)

The fundamental challenge of developing a long-acting growth hormone (LAGH) is to create a more convenient growth hormone (GH) dosing profile while retaining the excellent safety, efficacy and tolerability of daily GH. With GH receptors on virtually

Externí odkaz: https://doaj.org/article/101d45f6ef2a491b9de106f316779ed5

PaTH Forward:A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism

Autor: Peter Schwarz, Denka Markova, Alden Smith, Sanchita Mourya, Lars Rejnmark, Aimee D Shu, Intekhab Ahmed, David B Karpf, Tamara Vokes, Aliya Khan, Claudio Marcocci, Bart L. Clarke, Meryl Brod, Erik Fink Eriksen, Mishaela R. Rubin, Susanne Pihl, Uberto Pagotto, Andrea Palermo, Lorenz C. Hofbauer

Publikováno v: Khan, A A, Rejnmark, L, Rubin, M, Schwarz, P, Vokes, T, Clarke, B, Ahmed, I, Hofbauer, L, Marcocci, C, Pagotto, U, Palermo, A, Eriksen, E, Brod, M, Markova, D, Smith, A, Pihl, S, Mourya, S, Karpf, D B & Shu, A D 2022, ' PaTH Forward : A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of TransCon PTH in Adult Hypoparathyroidism ', Journal of Clinical Endocrinology and Metabolism, vol. 107, no. 1, pp. E372-E385 . https://doi.org/10.1210/clinem/dgab577
The Journal of Clinical Endocrinology and Metabolism

Context Hypoparathyroidism is characterized by insufficient levels of parathyroid hormone (PTH). TransCon PTH is an investigational long-acting prodrug of PTH(1-34) for the treatment of hypoparathyroidism. Objective This work aimed to investigate the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82c2cf0348e82835f0ff0a5670103b0b
https://curis.ku.dk/portal/da/publications/path-forward(e72390ee-4276-41d2-8b23-5d120efae605).html

Response to Letter to the Editor From L. Sävendahl et al: 'Weekly Lonapegsomatropin in Treatment-Naïve Children With Growth Hormone Deficiency: The Phase 3 heiGHt Trial'

Autor: Paul S Thornton, Aristides K Maniatis, Elena Aghajanova, Elena Chertok, Elpis Vlachopapadopoulou, Zhengning Lin, Wenjie Song, Eva Dam Christoffersen, Vibeke Miller Breinholt, Tatiana Kovalenko, Elene Giorgadze, Maria Korpal-Szczyrska, Paul L Hofman, David B Karpf, Aimee D Shu, Michael Beckert

Publikováno v: The Journal of Clinical Endocrinology and Metabolism

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0cbdd4d4089d262acb39747378781988
https://doi.org/10.1210/clinem/dgab738

Prevalence of hypoparathyroidism in the EU: A systematic review and meta-analysis

Autor: David B Karpf, Chelsea Catsburg, Alden Smith

Publikováno v: Endocrine Abstracts.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::571f92e33f9c30cc84518641ce6f065b
https://doi.org/10.1530/endoabs.70.aep140

SAT-LB72 Design of the PaTH Forward Phase 2 Trial of TransCon PTH, a Long-Acting PTH, in Patients With Hypoparathyroidism

Autor: Andrea Palermo, Mishaela R. Rubin, Lorenz C. Hofbauer, David B Karpf, Intekhab Ahmed, Sanchita Mourya, Claudio Marcocci, Aliya Khan, Lars Rejnmark, Erik Erikson, Tamara Vokes, Uberto Pagotto, Denka Markova, Bart L. Clarke, Peter Schwarz

Publikováno v: Journal of the Endocrine Society

Background: Hypoparathyroidism (HP) is caused by a deficiency in parathyroid hormone (PTH), which leads to hypocalcemia and hyperphosphatemia. Standard of care (SoC), i.e. large doses of calcium (Ca) and active vitamin D, worsens hypercalciuria and i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90e5b02f23d0f61296103d082531337f
https://doi.org/10.1210/jendso/bvaa046.2209